(This Aug 28 story has been repeated with no changes to text.) By Bhanvi Satija and Sriparna Roy Aug 28 (Reuters) - BioNTech ...
Moderna’s vaccine, intismeran, is a personalized neoantigen vaccine. It delivers mRNA that encodes tumor-specific mutations ...
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...
A vaccine manufacturer has said it is terminating a clinical trial testing an experimental vaccine against cancer. The vaccine, which utilizes messenger ribonucleic acid (mRNA) technology, is made by ...
In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the ...
Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to ...
For older adults, the flu vaccine could look a little different this year.
Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA ...
The US Food and Drug Administration on Wednesday approved the United States’ first mRNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results